title: Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown.
abstract: Flavone acetic acid (FAA), a novel investigational antitumor agent, has been shown to cause early vascular shutdown in several experimental murine tumors, and this phenomenon is believed to be crucial to FAA's antitumor effects. However, the basis of this FAA-induced tumor vascular shutdown is unknown. In this study a radioactive tracer-clearance technique has been used as an objective indication of tumor blood flow to show that i.p. administered FAA induces a progressive and sustained reduction in blood flow in a colon 26 tumor growing s.c. in syngeneic mice. As early as 1 h after administration, there was a significant increase in the t1/2 clearance value for intratumorally injected 133Xe, reaching a peak at 3 h (117.3 +/- 36.4 versus 7.8 +/- 0.85 min for controls). Significant inhibition of blood flow was still apparent 48 h after a single injection of drug. This FAA-induced vascular shutdown was virtually abolished in tumor-bearing mice pretreated with an antiserum against tumor necrosis factor, while no such effect was observed in controls pretreated with nonimmune serum (t1/2 of 10.8 +/- 1.2 versus 65.6 +/- 8.0 min for controls). Furthermore, in vitro FAA was seen to induce tumor necrosis factor secretion from murine peritoneal cells and splenocytes. These studies suggest that FAA-induced tumor vascular shutdown in the colon 26 tumor is mediated by tumor necrosis factor.
authors.affiliation: Imperial Cancer Research Fund Laboratories, London, England.
authors.forename: V
authors.initials: V
authors.lastname: Mahadevan
authors.forename: S T
authors.initials: ST
authors.lastname: Malik
authors.forename: A
authors.initials: A
authors.lastname: Meager
authors.forename: W
authors.initials: W
authors.lastname: Fiers
authors.forename: G P
authors.initials: GP
authors.lastname: Lewis
authors.forename: I R
authors.initials: IR
authors.lastname: Hart
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000098:blood supply* / Q000188:drug therapy / Q000473:pathology; D005419:Flavonoids / Q000627:therapeutic use*; D007106:Immune Sera; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D011994:Recombinant Proteins / Q000494:pharmacology; D012039:Regional Blood Flow / Q000187:drug effects*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology / Q000502:physiology*; D014980:Xenon Radioisotopes
chemical_list: D000970:Antineoplastic Agents; D005419:Flavonoids; D007106:Immune Sera; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D014980:Xenon Radioisotopes; C049328:flavone acetic acid